Tradestie Institutional Equity Comparison Engine
COCP vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Overall Edge
DMAC Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
COCP N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner
DMAC
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs +0.0%
Momentum & Technical Winner
DMAC
1Y -3.0% vs +55.3% ยท 52W Pos 19% vs 55%
Options & Structure Winner
DMAC
UNCLASSIFIED (N/A IV) vs SURGE (14th %ile IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap
$19.6M
1M Return
-2.01%
1Y Return
-2.96%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -2.96%
DMAC +55.26%
Spread: +58.22 pp (DMAC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | COCP Revenue | DMAC Revenue | COCP Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | $10M | N/A | -30.6% | N/A | COCP |
| FY2018 | N/A | $0M | N/A | -1352.2% | DMAC |
| FY2019 | $10M | N/A | -737.4% | N/A | COCP |
| FY2020 | $0M | N/A | -476.0% | N/A | COCP |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $503.1M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +26.9% | +0.0% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | -3063.6% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -114.6% | Higher ROE | DMAC |
| 52-Week Range Position Momentum | 19% ($1โ$2) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.04ฮฒ ยท 54% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | COCP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs DMAC Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.